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Background: In low- and middle-income countries, the association between delay to treatment and prognosis for
Kaposi’s sarcoma (KS) patients is yet to be studied.
Methods: This is a prospective study of HIV-infected adults with histologically-confirmed KS treated at the Uganda
Cancer Institute (UCI). Standardized interviews were conducted in English or Luganda. Medical records were
abstracted for KS stage at admission to UCI. Multivariable logistic regression assessed relationships between
diagnostic delay and stage at diagnosis.
Results: Of 161 patients (90% response rate), 69% were men, and the mean age was 34.0 years (SD 7.7). 26% had
been seen in an HIV clinic within 3 months, 72% were on antiretroviral therapy, and 26% had visited a traditional
healer prior to diagnosis. 45% delayed seeking care at UCI for ≥3 months from symptom onset. Among those who
delayed, 36% waited 6 months, and 25% waited 12 months. Common reasons for delay were lack of pain (48%), no
money (32%), and distance to UCI (8%). In adjusted analysis patients who experienced diagnostic delay were more
likely than those who did not delay to have poor-risk KS stage (OR 3.41, p = 0.002, 95% CI: 1.46-7.45). In adjusted
analyses visiting a traditional healer was the only variable associated with greater likelihood of delay
(OR 2.69, p = 0.020, 95% CI: 1.17-6.17).
Conclusions: Diagnostic delay was associated with poor-risk stage at diagnosis, and visiting a traditional healer was
associated with higher odds of delay. The relationship between traditional and Western medicine presents a critical
intervention point to improve KS-related outcomes in Uganda.
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The incidence of Kaposi’s sarcoma (KS) in sub-Saharan
Africa has increased since the advent of the HIV epidemic,
contributing an estimated 37,214 cases and 25,352 deaths
annually [1]. While incidence and mortality have de-
creased in high-income countries with the introduction of
antiretroviral therapy (ART), low-income countries have
seen the opposite, especially those in sub-Saharan Africa
that carry heavy burdens of HIV. Over the same period in
which the West saw a 24-fold decrease in incident KS,* Correspondence: chris.deboer09@gmail.com
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unless otherwise stated.Uganda and Zimbabwe experienced a 20-fold increase in
KS incidence among HIV-infected individuals [2,3]. This
has been attributed to the rise of HIV/AIDS and the lack
of antiretroviral therapy, which has been shown to be cru-
cial for KS tumor regression, decreasing viral loads, and
raising CD4 counts. [4-9]. Because of these factors, KS is
now the most common cancer among HIV-infected men
in SSA and the second most common in women after
cervical cancer [1].
In Uganda, KS contributes 3,635 annual incident cases
with 2,637 annual deaths [1]. Previous research has pointed
to a lack of coverage with ART, gender differences, and
high seroprevalence of human herpesvirus type 8 (HHV-8),
the causative agent of KS, to explain poor patient outcomes
in Uganda [9-11]. ART coverage in the country remainsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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pite prompt treatment with ART [12]. Other patients have
experienced immune reconstitution inflammatory syn-
drome (IRIS) after the initiation of ART, causing a prolifera-
tion of KS [13]. While these explanations offer some insight
into the poor patient outcomes for KS patients in Uganda,
numerous factors remain unexamined, particularly those
concerning the health system and access to cancer care for
KS patients.
Diagnostic delay has been assessed as a health system
factor that can influence cancer stage and patient progno-
sis among specific cancers in developed countries [13-17].
One type of delay that has been shown to be associated
with poor patient prognoses is “primary” delay, defined
as waiting longer than three months after noticing signs
and symptoms before presentation to a clinician [18-20].
Other types of delay are traditionally defined as secondary
delay, the time from presentation to a clinician until diag-
nosis, and tertiary delay, the time from diagnosis to initi-
ation of treatment [18]. A search of the literature did not
reveal any known associations between KS stage with
diagnostic delay at any stage in low- and middle-income
countries (LMICs). Further, we could not find an analysis
of this association with respect to HIV-associated malig-
nancies in any context. Therefore, the primary aim of this
study was to measure the association between primary
delay and the cancer stage of HIV-KS patients upon diag-
nosis of the disease by a clinician. We hypothesized that
those who experienced primary delay would be more




This was a cross-sectional, prospective study to measure
the association between diagnostic delay, specifically pri-
mary delay greater than three months, and having an
overall poor HIV-associated KS stage risk. Staging data
were abstracted from chart records, and history of diag-
nostic delay was gathered through standardized interviews.
Patients who reported waiting longer than three months
after noticing signs and symptoms before reporting this to
any health professional were defined as “delayers”. The
cutoff of three months was established based on previ-
ous literature examining delay within cancer populations
that has utilized and validated the same value [14,18-20].
Medical record data and standardized interviews com-
pleted in English and Luganda were utilized to obtain data
on the history of exposure to ART, presence of primary,
secondary, and tertiary delay, and patient demographics.
A cutoff of three weeks was established for secondary and
tertiary delay, which was the suggested value from clini-
cians at the UCI familiar with the local health system and
the patient population.We utilized the prospectively validated staging system
for AIDS-associated Kaposi sarcoma as designed by the
AIDS Clinical Trials Group (ACTG), which is used by
physicians at the UCI [21]. Patients were dichotomized
as either having overall “good risk” or “poor risk” based
on this system, which designates good or poor risk in
three diagnostic areas: extent of tumor involvement (T),
immune system function (I), and presence of systemic
illness (S). A patient with poor risk in all three areas,
(T1I1S1), is defined as having overall poor risk as their
HIV-KS stage. Poor risk for extent of tumor involvement
is described as having any tumor-associated edema, exten-
sive raised KS, oral KS nodules not confined to the palate,
or any KS of the gastrointestinal tract or any other non-
nodal viscera. Good risk for tumor extent indicates that all
KS nodules, or lesions, are confined to the skin or lymph
nodes, and any oral involvement is confined to the palate
only. Poor risk for immune system function is defined as
any patient that has a CD4 count that is ≤ 150 cells per
cubic microliter as per the modification to the staging
system made by the ACTG and implemented at the UCI
[22]. For presence of systemic illness, poor risk is de-
fined as having any history of opportunistic infections, or
the presence of “B” symptoms, or any other HIV-related
illness (e.g. neurologic disease, lymphoma). B symptoms
are defined as the presence of HIV-associated illness by
the CDC Clinical Category B, which includes drenching
night sweats, greater than 10% body weight loss, unex-
plained fevers, or diarrhea persisting for greater than
two weeks.
The ACTG staging system has been prospectively vali-
dated to link stage and survival in both resource rich
and resource limited contexts [22,23]. In a high-income
setting, survival was significantly shorter for patients
that displayed poor risk in each diagnostic category with
the Immune status (I) and Tumor extent (T) categories
being most predictive of survival, but Systemic symptoms
(S) was not [22]. In a resource limited setting, however,
the T and S categories were associated with survival, but
the I diagnostic category was only associated with survival
when establishing a cutoff of CD4 counts at <100 cells/
microliter [23]. The authors of that study concluded that
more research is needed to examine the implementa-
tion of the ACTG staging system in populations in sub-
Saharan Africa given different prognostic factors. This
study represents an opportunity to implement the sys-
tem in such a setting to see if delay is a prognostic
factor that influences ACTG stage among KS patients
upon admission.
Study population
Eligible participants were HIV seropositive out-patients
with histologically confirmed AIDS-associated Kaposi’s
sarcoma. The study was performed at the Uganda Cancer
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cancer treatment center in the country, from June-October
2012. Although the UCI provides treatment for free for KS
patients, transportation and other costs associated with
care are considerable challenges for many patients. The
study was performed among adults (≥18 years old) who














<100,000 UGSH 63 57.3






Tertiary or Degree 14 12.2
Total 115 100.0













< 3 months 73 63.5
> = 3 months 42 36.6
Total 115 100.0
*Unadjusted, using Pearson’s Chi-Square test.seropositive, and had a CD4 count performed within the
previous six months. Patients with a history of immune
reconstitution inflammatory syndrome (IRIS), who would
be severely ill, were excluded from the study, although we
did not encounter any of these individuals through the
interview process, most likely due to our focus on the out-
patient population.ge risk
age risk
Poor risk Total P-Value*
N % N %
37 80.4 111 68.9
9 19.6 50 31.1 0.046
46 100.0 161 100.0
9 20.0 44 28.0
26 57.8 85 54.1
10 22.2 28 17.8 0.319
45 100.0 157 100.0
27 60.0 90 58.1
14 31.1 59 38.1
4 8.9 6 3.9 0.083
45 100.0 155 100.0
26 56.5 83 51.6
14 30.4 58 36.0
6 13.0 20 12.4 0.642
46 100.0 161 100.0
36 78.3 93 57.8
10 21.7 68 42.2 0.001
46 100.0 161 100.0
11 23.9 41 25.5
35 76.1 120 74.5 0.872
46 100.0 161 100.0
17 37.0 44 28.4
29 63.0 111 71.6 0.124
46 100.0 155 100.0
15 32.6 88 54.7
31 67.4 73 45.3
46 100.0 161 100.0 <0.001
Table 2 Primary findings: distribution of primary delay




<3 Months 88 54.7
≥ 3 Months 73 45.3
Overall stage risk
Good risk 115 71.4
Poor risk 46 28.6
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Descriptive statistics were measured using means with
standard deviations and percentages to obtain prevalence
of delay, mean ages, age distribution, and prevalence of
different staging criteria. Pearson’s Chi-Square test was
utilized for unadjusted analyses. Multivariate logistic
regression with a generalized linear model assumption
with binary outcomes was implemented to model all ad-
justed associations and obtain prevalence odds ratios. A
multivariate model was created to measure the association
between primary delay and an overall poor stage risk,
adjusting for age, gender, ability to pay out-of-pocket, in-
come, and exposure to ART. Gender was included in the
model because it was significantly associated with overall
poor stage risk in the univariate analysis (Table 1). Age,
income, and exposure to ART were anchored in the
model based on clinical knowledge and previous litera-
ture that suggested their association with delay and cancer
prognosis [10,11].
Of note, ability to pay out-of-pocket, a dichotomous
variable referring to a patient’s ability to pay any cash
out of pocket for any previous KS treatment before pres-
entation to UCI, was significantly associated with overall
poor stage risk in unadjusted analysis (Table 1). We de-
termined that this variable was a strong modifier and
important protective factor in the relationship between
primary delay and overall stage risk as a proxy for a pa-
tient’s wealth but not an independent determinant of
overall poor stage risk.
Characteristics that were significantly associated with pri-
mary delayers in unadjusted analyses were implemented in
a second multivariate model to measure its association with
primary delay, adjusting for age, gender, income, ability to
pay-out-of pocket, and exposure to ART. These covariates
were anchored in the model based on clinical knowledge
and previous literature that suggested they may be associ-
ated with the variables of interest [10-12]. Data were stored
in Microsoft Excel 2010 and analyzed using Stata/SE v.11.0
(College Station, Texas).
Funding source and ethical approval
This study was funded by the Master of Science in Global
Health Student Research Grant from the Duke Global
Health Institute in Durham, NC. Ethical approval was
provided by Duke University Institutional Review Board
for Research with Human Subjects and the Makerere Col-
lege of Health Sciences Research Ethics Committee.
Results
From June 22 to October 30, 2012, 178 consecutive AIDS-
associated KS patients treated at the Uganda Cancer
Institute as out-patients were approached for partici-
pation; 168 agreed to participate and 7 surveys were
discarded due to data quality issues (90% response rate).Sixty-nine percent were men, and the mean age was
34 years (SD: 7.7) with a slightly lower age distribution for
women, although the mean age was not significantly
different between men and women (p = 0.13). Fifty-eight
(35%) of all participants were unemployed, and 49 percent
had at least a primary education. Among all participants,
149 (93%) had previously received some form of treatment
at an HIV clinic upon admission to UCI, and 106 (72%) of
all participants were taking antiretroviral therapy (ART).
Of those, 77 had been exposed to ART for at least three
months prior to enrollment. Twenty-six percent of all par-
ticipants reported visiting a traditional healer prior to their
admission to UCI (Table 1).
Among all patients, 73 (45%) experienced primary diag-
nostic delay longer than three months (Table 2). Among
those who delayed, 26 (36%) waited for more than
6 months, while 18 (25%) waited for more than 12 months
prior to seeking medical attention for KS-related symp-
toms. Lack of pain (48%), lack of money for transportation
(32%), and distance to UCI (8%) were cited as the most
common reasons for delay. In addition, 46 (29%) had an
overall poor risk as their KS stage upon admission (Table 2).
Ninety-two percent of all patients presented with poor risk
in the tumor extent category (T), 40% of patients had a
CD4 count less than 150 cells/microliter, categorizing them
as poor risk with respect to immune system function (I),
and 73% had poor risk with respect to presence of systemic
illness (S). In multivariate analysis after adjusting for
gender, age, income, and exposure to ART, patients who
experienced diagnostic delay were more than three times
as likely to have poor-risk stage at presentation compared
to those who did not delay (OR 3.41, p = 0.002, 95%CI:
1.46-7.45) (Figure 1, Table 3).
In addition to primary delay, data were collected on
the secondary delay and tertiary delay that was experi-
enced by participants. Forty-seven (29%) patients experi-
enced secondary delay longer than one month, while 26
(16%) experienced delay less than one week. Twenty-one
(13%) patients experienced tertiary delay greater than
90 days, and the median delay time was 23 days (IQR:
11–47) with a mean delay of 42.7 days (SD: 53.1) (Table 4).
Figure 1 Plot of Odds Ratios for the association between primary delay and overall poor stage risk with selected covariates.
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the secondary and tertiary stages revealed that 89% of the
cohort experienced at least one type of delay, and 8% ex-
perienced delay at every stage from first noticing symp-
toms until diagnosis.
Multivariate analyses were also performed to measure
associations between patient characteristics and experi-
encing diagnostic delay. After adjusting for gender, age,
income, ability to pay out-of-pocket, and previous HIV
clinic attendance, only visitation to a traditional healer
was associated with experiencing diagnostic delay (OR
2.69, p = 0.020, 95% CI: 1.17-6.17). Previous HIV clinic
attendance and duration on ART were not associated
with delay (Figure 2, Table 5).
Discussion
Early diagnosis of cancer is an aim of cancer care and
control programs worldwide, especially among LMICs that
are experiencing a burgeoning cancer burden. This is par-
ticularly true for cancer care for HIV-associated malig-
nancies that can leverage current HIV programs to detectTable 3 Multivariate Logistic regression with selected
covariates measuring the association between primary
delay and overall poor stage risk
Variable Odds ratio Std. Err. P > |0.05| [95% Conf.
Interval]
Primary delay 3.41 1.36 0.002 1.46 - 7.45
Selected covariates
Gender 0.50 0.23 0.144 0.19 - 1.27
Age 1.64 0.50 0.102 0.91 - 2.97
Income 1.00 0.35 0.992 0.51 - 1.99
Exposure to ART 0.60 0.25 0.216 0.26 - 1.35cancer faster. Measuring delay can be an important step
in better understanding patient outcomes, particularly in
the context of under-resourced health systems. While
numerous studies have offered theoretical frameworks
for understanding delay, few have measured these delays
across the entire continuum from first notice of signs and
symptoms until treatment [18,24]. Moreover, to the best of
our knowledge, none have examined delays and their influ-
ence on cancer stage or patient outcomes in resource-poor
areas or delays with respect to HIV-associated malignan-
cies in any context.
In response to this gap in understanding, this study
measured the association between primary delay and the
cancer stage upon admission among Kaposi’s sarcoma<3 Months 88 54.7
≥ 3 Months 73 45.3
Secondary delay
>1 Week 26 16.1
2 Weeks - 1 Month 88 54.7
>1 Month 47 29.2
Tertiary delay
0-7 Days 20 12.4
8-30 Days 73 45.3
31-90 Days 47 29.2
>90 Days 21 13.0
Figure 2 Plot of Odds Ratios for the association between visitation to a traditional healer and primary delay with selected covariates.
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ation between primary delay and the KS cancer stage upon
admission to a cancer referral center, and second, that
delay can be a key point of intervention to improve overall
KS stage risk. In this study, HIV-infected KS patients who
experienced primary delay were more than three times as
likely to have an overall poor stage risk at presentation
compared those who did not experience primary delay.
It is still unclear, however, how delay for KS patients
and the effect of these delays in Uganda compares to
other cancers given the dearth of data and inadequacy
of comparing studies assessing cancer in high-income
countries only [25-27].
Our study found far more patients (92%) presented
with poor risk KS in the tumor extent category than in
other studies, which suggest approximately 64% present
with poor-risk disease [22,28]. However, these studies also
lack comparative power since they evaluated patients in
high-income settings. Later stage at diagnosis in our study
is most likely reflective of diagnostic delay related to healthTable 5 Multivariate logistic regression with selected
covariates measuring the association between visitation
to a traditional healer and primary delay




2.69 1.14 0.021 1.17 – 6.17
Selected Covariates
Gender 0.91 0.42 0.835 0.37 – 2.25
Age 1.03 0.32 0.909 0.56 – 1.19
Income 0.50 0.21 0.092 0.23 – 1.11
Pay out-of-pocket 0.96 0.40 0.923 0.43 – 2.17
Exposure to HAART 0.79 0.34 0.581 0.34 – 1.84system factors, especially concerning the role of traditional
healers and the need for improvement among HIV health
workers to recognize KS symptoms, as the majority of the
cohort was previously exposed to HIV care. Much of the
success in treating KS in high-income countries has been
attributed to effective HIV referral systems that recognize
KS signs and symptoms, along with widely available ART
[26,27,29-31].
Rates of secondary and tertiary delays were lower in
this cohort than in other studies [24,28]. These findings
suggest that once primary delay is overcome, the health
system at UCI performed better than those in compar-
able studies with respect to minimizing secondary and
tertiary delay. These results should be interpreted with
caution, however, as a large majority of the cohort (89%)
experienced at least one type of delay and 8% experi-
enced delay at every stage, leading to additive, lengthy
delays across the care continuum. Further work should
be done to examine the causes for lengthy delays at each
point of the care continuum and role of the health sys-
tem in creating delays.
The only patient characteristic associated with diagnostic
delay in multivariate analysis was visitation to a traditional
healer, which has been acknowledged in the literature
as a competing source of healthcare and as a possible
marker of poorer outcomes for cancer patients [29].
Traditional healers remain an important part of Ugandan
societal norms, and results from this study suggest that
working with traditional healers might present an import-
ant point of intervention to reduce delay.
Other results reveal an important opportunity for early
KS detection that may be overlooked. A large proportion
of this cohort was already exposed to the healthcare
system via HIV care prior to admission to UCI. Though
many patients developed signs and symptoms while seeking
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patients enrolled in HIV care were no less likely to delay,
this may present another opportunity for intervention.
HIV/AIDS treatment programs have strategically lever-
aged their care infrastructure to target non-communicable
diseases, but our data suggest more work needs to be
done to ensure appropriate screening in this at-risk popu-
lation [31]. Our study was not designed or powered to
examine the relationship between HIV care and delay, but
we did find that 93% of patients received some sort of
treatment at an HIV clinic before admission to the UCI
and that at least 41 patients (25%) were actually in HIV
care when they developed signs and symptoms of KS, and
15 (37%) of these patients waited longer than three months
before presenting to a clinician for those symptoms. Our
study was not designed to analyze this finding that came
out of our study, and more research is needed to examine
the influence of previous HIV care on delay among KS
patients in Uganda.
Our study is subject to limitations. Possible sources of
bias include recall bias in determining delay and selection
bias by interviewing patients only at a central referral cen-
ter, potentially missing those were severely ill or those who
improved on ARTalone in their local clinic. The study only
included out-patients, which may have led to an underrep-
resentation of severely ill patients. In addition, this repre-
sents one of the first studies implementing the ACTG
staging system in a low-income setting with a population
exposed to ART, and previous literature has shown that
modification in staging for this population is necessary
[23]. More research on the staging in the post-ART area
is needed not only for KS, but other cancers as well
[22,23,28,31].
In conclusion, reducing delay can be an important point
of intervention for improving KS outcomes in Uganda.
This is especially true for AIDS-associated malignancies
with faster progression. In addition, leveraging traditional
healers and pre-existing HIV referral system infrastructure
to screen for cancer may be possible solutions. Finally,
further investigations should examine the efficacy of KS
staging in low-income settings of high ART exposure.
While significant challenges exist for KS control in Uganda,
these findings identify key interventions that can target
inefficiencies in the health system and increase local
cancer knowledge for faster KS referrals and better pa-
tient prognoses.
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